News | January 07, 2024
AOB Pharma and Maruho enter into an agreement for AOB’s B244 for treatment of atopic dermatitis in Japan
The deal includes upfront payments, milestone payments and ongoing royalties
The deal includes upfront payments, milestone payments and ongoing royalties
Comprehensive clinical development programs being initiated for each investigational candidate
Base4's drug discovery platform allows its collaborators to evaluate billions of novel small molecules to identify and progress RNA-modulators for important diseases
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
The bioprocess business will continue to pioneer contributions to safety and productivity in the manufacture of biotherapeutics
KBR will provide outreach, education and data analytics to support critical neuroscience research for the prevention and treatment of military members with CTE
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Subscribe To Our Newsletter & Stay Updated
